News Briefing channel feed

Aldeyra bags PhI­II-ready eye drug in He­lio buy­out; Liq­uid biop­sy mak­er On­co­Cyte shares sky­rock­et on val­i­da­tion da­ta

7 years ago

The FDA is back in busi­ness; Al­lo­gene giv­en the green sig­nal to test lym­phoma drug in hu­mans

7 years ago

Ab­b­Vie shares slide on slid­ing Hu­mi­ra rev­enue; Deer­field is mak­ing a big in­vest­ment in new de­vice star­tups

7 years ago

Rit­ux­an copy­cat pass­es first piv­otal test for Am­gen, Al­ler­gan; Iron­wood and biotech spin­out name new boards

7 years ago

RNAi leader Al­ny­lam inks col­lab­o­ra­tion pact with start­up; GV's Rosana Kapeller joins Schrödinger board

7 years ago

EC ex­pands ap­proval of Am­gen's Blin­cy­to; FDA gives uniQure green sig­nal to be­gin Hunt­ing­ton's study in hu­mans, Cy­to­ki­net­ics feed­back on SMA tri­al

7 years ago

Tyme flops on can­cer drug da­ta; Lil­ly IND fil­ing trig­gers $8M pay­ment to part­ner Zymeworks

7 years ago

Bay­er ax­ing 665 work­ers at US cam­pus; NASH biotech pumps up share price with an ‘in­ter­im’ snap­shot

7 years ago

As­traZeneca signs deal to pro­mote prod­uct made in Chi­na — in main­land Chi­na; Is­raeli deep brain stim­u­la­tion co Brain­sway sets stage for $30M Nas­daq IPO

7 years ago

Seres pro­motes CFO Er­ic Shaff to suc­ceed Pomer­antz as CEO; Ex­elix­is' Cabome­tyx bags US ap­proval for liv­er can­cer

7 years ago

FDA of­fers Pfiz­er pri­or­i­ty re­view for tafamidis; Clar­i­vate to merge with Churchill Cap­i­tal

7 years ago

CAN­bridge ex­pands rare dis­ease pact with WuXi Bi­o­log­ics; Watch for a man­u­fac­tur­ing site from Al­lo­gene

7 years ago

Roche names new Foun­da­tion Med chief; Ako­rn shares dip on FDA warn­ing let­ter; Zai Lab ad­vances piv­otal PARP study

7 years ago

Lil­ly to dis­play drug pric­ing in­fo on web­site; Catal­ent pledges $200M for its bi­o­log­ics unit

7 years ago

Pos­i­tive oc­u­lar im­plant da­ta bring Al­ler­gan one step clos­er to NDA; Vivek Ra­maswamy spawns an­oth­er 'Van­t'

7 years ago

Aim­mune en­ters in­to loan agree­ment with KKR; Boehringer bags rights to sec­ond RNAi drug from Dicer­na

7 years ago

Ver­tex beefs up gene-edit­ing work with new dis­cov­ery pact; Ver­ri­ca shares jump on mol­lus­cum drug da­ta; J&J's inks two deals

7 years ago

Stealth Bio posts plans for $86M IPO; Sanofi out-li­cens­es drug for neu­roen­docrine-re­lat­ed dis­ease

7 years ago

G1 touts PhII can­cer da­ta, but shares tank on place­bo re­sults; Mer­ck bags an­oth­er ap­proved in­di­ca­tion for Keytru­da

7 years ago

Vivek Ra­maswamy bags op­tion rights on Dai­ichi’s pipeline drugs; Achillion drops a lead pro­gram; Zio­pharm cre­ates new de­vel­op­ment com­pa­ny for Chi­na

7 years ago

No­vo helps birth start­up ad­vanc­ing an As­traZeneca castoff with $15M; Japan's Fu­ji Phar­ma wa­gers $50M on Alvotech's biosim­i­lars

7 years ago

Ver­tex CFO Thomas Graney ex­its abrupt­ly; Eli Lil­ly touts a head-to-head win over Hu­mi­ra

7 years ago

Lil­ly, In­cyte's baric­i­tinib wins fast-track sta­tus for hard-to-treat lu­pus; Syn­thorx ham­mers out $150M+ IPO

7 years ago

Art Krieg moves from CEO post to CSO at Check­mate; In­di­v­ior breathes sigh of re­lief af­ter court rul­ing

7 years ago
First page Previous page 53545556575859 Next page Last page
A service from the Financial Times